Rafoxanide negatively modulates STAT3 and NF ‐ κB activity and inflammation‐associated colon tumorigenesis
Cancer Science · 2024-11 · 115 (11) · 3596-3611
DOI: 10.1111/cas.16317 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 06.09.2024. Verfasst von Teresa Pacifico und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, NF-kappa B, Cell Proliferation, Rafoxanide. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fondazione AIRC per la Ricerca sul Cancro ETS, Ministero dell'Università e della Ricerca (MUR).
Abstract (Originalsprache)
In the colorectal cancer (CRC) niche, the transcription factors signal transducer and activator of transcription 3 (STAT3) and nuclear factor‐κB (NF‐κB) are hyperactivated in both malignant cells and tumor‐infiltrating leukocytes (TILs) and cooperate to maintain cancer cell proliferation/survival and drive protumor inflammation. Through drug repositioning studies, the anthelmintic drug rafoxanide has recently emerged as a potent and selective antitumor molecule for different types of cancer, including CRC. Here, we investigate whether rafoxanide could negatively modulate STAT3/NF‐κB and inflammation‐associated CRC. The antineoplastic effect of rafoxanide was explored in a murine model of CRC resembling colitis‐associated disease. Cell proliferation and/or STAT3/NF‐κB activation were evaluated in colon tissues taken from mice with colitis‐associated CRC, human CRC cells, and CRC patient‐derived explants and organoids after treatment with rafoxanide. The STAT3/NF‐κB activation and cytokine production/secretion were assessed in TILs isolated from CRC specimens and treated with rafoxanide. Finally, we investigated the effects of TIL‐derived supernatants cultured with or without rafoxanide on CRC cell proliferation and STAT3/NF‐κB activation. The results showed that rafoxanide restrains STAT3/NF‐κB activation and inflammation‐associated colon tumorigenesis in vivo without apparent effects on normal intestinal cells. Rafoxanide markedly reduces STAT3/NF‐κB activation in cultured CRC cells, CRC‐derived explants/organoids, and TILs. Finally, rafoxanide treatment impairs the ability of TILs to produce protumor cytokines and promote CRC cell proliferation. We report the novel observation that rafoxanide negatively affects STAT3/NF‐κB oncogenic activity at multiple levels in the CRC microenvironment. Our data suggest that rafoxanide could potentially be deployed as an anticancer drug in inflammation‐associated CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
- Inflammatory Bowel Disease Research Laboratory, Department of Biological Sciences, Institute of Biotechnology, Federal University of Catalão (UFCAT), Catalão, Brazil.
- Department of Surgery, University of Rome "Tor Vergata", Rome, Italy.
- Neuroimmunology Unit, Santa Lucia Foundation IRCCS, Rome, Italy.
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
ORCID-Profile: Federica Laudisi
Förderung
- Fondazione AIRC per la Ricerca sul Cancro ETS
- Ministero dell'Università e della Ricerca (MUR)
Zitieren
APA
Pacifico, T., Stolfi, C., Tomassini, L., Luiz-Ferreira, A., Franzè, E., Ortenzi, A., Colantoni, A., Sica, G. S., Sambucci, M., Monteleone, I., Monteleone, G., & Laudisi, F. (2024). Rafoxanide negatively modulates STAT3 and NF ‐ κB activity and inflammation‐associated colon tumorigenesis. Cancer Science, 115(11), 3596-3611. https://doi.org/10.1111/cas.16317
Vancouver
Pacifico T, Stolfi C, Tomassini L, Luiz-Ferreira A, Franzè E, Ortenzi A, et al. Rafoxanide negatively modulates STAT3 and NF ‐ κB activity and inflammation‐associated colon tumorigenesis. Cancer Science. 2024;115(11):3596-3611. doi:10.1111/cas.16317
BibTeX
@article{Pacifico2024,
author = {Pacifico, Teresa and Stolfi, Carmine and Tomassini, Lorenzo and Luiz-Ferreira, Anderson and Franzè, Eleonora and Ortenzi, Angela and Colantoni, Alfredo and Sica, Giuseppe S and Sambucci, Manolo and Monteleone, Ivan and Monteleone, Giovanni and Laudisi, Federica},
title = {Rafoxanide negatively modulates STAT3 and NF ‐ κB activity and inflammation‐associated colon tumorigenesis},
journal = {Cancer Science},
year = {2024},
volume = {115},
number = {11},
pages = {3596--3611},
doi = {10.1111/cas.16317}
}
EUVIMED